Total Payments
$762,206
2024 Payments
$120,657
Companies
71
Transactions
1,255
Medicare Patients
10,768
Medicare Billing
$2.9M
Payment Breakdown by Category
Other$529,736 (69.5%)
Consulting$151,578 (19.9%)
Travel$34,960 (4.6%)
Food & Beverage$26,012 (3.4%)
Research$18,194 (2.4%)
Education$1,709 (0.2%)
Gifts$16.65 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $393,859 | 166 | 51.7% |
| Consulting Fee | $151,578 | 62 | 19.9% |
| Current or prospective ownership or investment interest | $108,181 | 3 | 14.2% |
| Travel and Lodging | $34,960 | 132 | 4.6% |
| Food and Beverage | $26,012 | 821 | 3.4% |
| Honoraria | $18,370 | 11 | 2.4% |
| Unspecified | $18,194 | 22 | 2.4% |
| Acquisitions | $6,827 | 2 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $2,500 | 1 | 0.3% |
| Education | $1,709 | 34 | 0.2% |
| Gift | $16.65 | 1 | 0.0% |
Payments by Type
General
$744,012
1,233 transactions
Research
$18,194
21 transactions
Ownership
$0
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $130,306 | 180 | $0 (2024) |
| Boston Scientific Corporation | $115,080 | 8 | $0 (2023) |
| Astellas Pharma US Inc | $100,646 | 176 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $81,345 | 105 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $55,941 | 165 | $0 (2024) |
| PFIZER INC. | $45,303 | 109 | $0 (2024) |
| Myovant Sciences Inc. | $36,323 | 21 | $0 (2022) |
| Merck Sharp & Dohme LLC | $29,187 | 49 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $28,148 | 29 | $0 (2024) |
| SUN PHARMACEUTICAL INDUSTRIES INC. | $27,124 | 28 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $120,657 | 215 | Janssen Biotech, Inc. ($35,974) |
| 2023 | $143,091 | 223 | Astellas Pharma US Inc ($28,747) |
| 2022 | $102,735 | 168 | Myovant Sciences Inc. ($26,557) |
| 2021 | $71,113 | 119 | Janssen Biotech, Inc. ($13,905) |
| 2020 | $68,037 | 105 | Bayer HealthCare Pharmaceuticals Inc. ($14,792) |
| 2019 | $86,127 | 170 | Janssen Biotech, Inc. ($24,922) |
| 2018 | $152,321 | 132 | BOSTON SCIENTIFIC CORPORATION ($102,989) |
| 2017 | $18,125 | 123 | Astellas Pharma US Inc ($11,529) |
All Payment Transactions
1,255 individual payment records from CMS Open Payments — Page 51 of 51
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/09/2017 | Astellas Pharma US Inc | Myrbetriq (Drug) | Education | In-kind items and services | $4.69 | General |
| Category: Urology | ||||||
| 01/08/2017 | Astellas Pharma US Inc | Myrbetriq (Drug), Xtandi | Food and Beverage | In-kind items and services | $8.40 | General |
| Category: Urology | ||||||
| 01/04/2017 | Astellas Pharma US Inc | Xtandi (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,600.00 | General |
| Category: Oncology | ||||||
| 01/04/2017 | Astellas Pharma US Inc | Xtandi (Drug) | Travel and Lodging | In-kind items and services | $108.00 | General |
| Category: Oncology | ||||||
| 2017 | AUGMENIX, INC. | — | — | — | $0.00 | Ownership |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CANCER | Eli Lilly and Company | $7,014 | 4 |
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $4,470 | 3 |
| XTANDI CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $3,980 | 2 |
| Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK) | Astellas Pharma Global Development | $2,174 | 8 |
| A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance (ENACT) | Astellas Pharma Global Development | $466.33 | 2 |
| A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | Eli Lilly and Company | $89.70 | 2 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 33 | 2,890 | 31,033 | $2.2M | $615,322 |
| 2022 | 26 | 2,627 | 23,138 | $1.7M | $421,190 |
| 2021 | 28 | 2,450 | 21,263 | $1.7M | $399,813 |
| 2020 | 37 | 2,801 | 28,111 | $4.0M | $1.5M |
Total Patients
10,768
Total Services
103,545
Medicare Billing
$2.9M
Procedure Codes
124
All Medicare Procedures & Services
124 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 72 | 17,280 | $720,058 | $313,362 | 43.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 65 | 474 | $711,000 | $64,544 | 9.1% |
| J1952 | Leuprolide injectable, camcevi, 1 mg | Office | 2023 | 21 | 1,008 | $198,576 | $63,894 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 295 | 552 | $146,280 | $50,218 | 34.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 364 | 516 | $92,880 | $31,394 | 33.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 39 | 265 | $32,860 | $12,662 | 38.5% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 58 | 60 | $43,800 | $10,549 | 24.1% |
| J9155 | Injection, degarelix, 1 mg | Office | 2023 | 11 | 3,040 | $30,200 | $9,775 | 32.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 631 | 901 | $9,926 | $7,360 | 74.2% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 35 | 40 | $14,200 | $5,453 | 38.4% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 23 | 23 | $15,525 | $4,449 | 28.7% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 18 | 95 | $11,685 | $4,429 | 37.9% |
| J9030 | Bcg live intravesical instillation, 1 mg | Office | 2023 | 23 | 1,800 | $11,520 | $3,962 | 34.4% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 90 | 139 | $10,981 | $3,646 | 33.2% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 59 | 65 | $11,960 | $3,221 | 26.9% |
| 51720 | Instillation of anti-cancer drug into bladder | Office | 2023 | 29 | 43 | $9,245 | $2,867 | 31.0% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 59 | 67 | $7,035 | $2,664 | 37.9% |
| 99439 | Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 31 | 71 | $6,674 | $2,544 | 38.1% |
| 51728 | Complex measurement of pressure of urine flow in bladder with voiding pressure studies | Office | 2023 | 12 | 12 | $6,881 | $2,421 | 35.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 584 | 1,012 | $12,144 | $2,196 | 18.1% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 27 | 36 | $6,588 | $2,182 | 33.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 70 | 164 | $10,168 | $1,807 | 17.8% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 20 | 20 | $5,420 | $1,585 | 29.2% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Office | 2023 | 12 | 12 | $3,625 | $1,407 | 38.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 11 | 11 | $4,400 | $1,306 | 29.7% |
About Dr. Christopher Pieczonka, M.D
Dr. Christopher Pieczonka, M.D is a Urology healthcare provider based in Syracuse, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1376530121.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Christopher Pieczonka, M.D has received a total of $762,206 in payments from pharmaceutical and medical device companies, with $120,657 received in 2024. These payments were reported across 1,255 transactions from 71 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($393,859).
As a Medicare-enrolled provider, Pieczonka has provided services to 10,768 Medicare beneficiaries, totaling 103,545 services with total Medicare billing of $2.9M. Data is available for 4 years (2020–2023), covering 124 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Syracuse, NY
- Active Since 10/05/2005
- Last Updated 06/22/2012
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1376530121
Products in Payments
- GENERAL THERAPIES (Device) $102,989
- ERLEADA (Drug) $90,374
- Xtandi (Drug) $63,824
- ORGOVYX (Drug) $61,081
- Erleada (Drug) $59,427
- PROVENGE (Drug) $58,765
- XTANDI (Drug) $55,824
- Nubeqa (Drug) $55,123
- YONSA (Drug) $27,124
- Xofigo (Drug) $23,059
- LYNPARZA (Drug) $19,003
- KEYTRUDA (Biological) $16,675
- GENERAL - THERAPIES (Device) $9,624
- PLUVICTO (Drug) $8,042
- SUTENT (Drug) $7,969
- ELIGARD (Drug) $6,538
- TALZENNA (Drug) $6,409
- LYNPARZA (Biological) $4,076
- OPDIVO (Biological) $3,640
- GENERAL THERAPIES (Device) $2,395
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Syracuse
Dr. David Albala, M.d, M.D
Urology — Payments: $212,162
Urology $212,162
Andrew Stephenson, Md, MD
Urology — Payments: $101,790
Urology $101,790
Dr. Scott Wiener, Md, MD
Urology — Payments: $43,281
Urology $43,281
Dr. Joseph Jacob, Md, MD
Urology — Payments: $36,165
Urology $36,165
Po Lam, Md, MD
Urology — Payments: $32,938
Urology $32,938
Ilija Aleksic, M.d, M.D
Urology — Payments: $16,486
Urology $16,486